Research progress in molecular classification of gastric cancer.
- Author:
Menglong ZHOU
;
Guichao LI
;
Zhen ZHANG
1
Author Information
1. Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China. zhenzhang7@163.com.
- Publication Type:Journal Article
- MeSH:
Asian Continental Ancestry Group;
Carcinogenesis;
genetics;
Disease Progression;
Early Detection of Cancer;
Epigenesis, Genetic;
physiology;
High-Throughput Nucleotide Sequencing;
Humans;
Microarray Analysis;
Molecular Epidemiology;
standards;
Mutation;
physiology;
Prognosis;
Stomach Neoplasms;
classification;
genetics
- From:
Chinese Journal of Gastrointestinal Surgery
2016;19(9):1072-1076
- CountryChina
- Language:Chinese
-
Abstract:
Gastric cancer(GC) is a highly heterogeneous malignancy. The present widely used histopathological classifications have gradually failed to meet the needs of individualized diagnosis and treatment. Development of technologies such as microarray and next-generation sequencing (NGS) has allowed GC to be studied at the molecular level. Mechanisms about tumorigenesis and progression of GC can be elucidated in the aspects of gene mutations, chromosomal alterations, transcriptional and epigenetic changes, on the basis of which GC can be divided into several subtypes. The classifications of Tan's, Lei's, TCGA and ACRG are relatively comprehensive. Especially the TCGA and ACRG classifications have large sample size and abundant molecular profiling data, thus, the genomic characteristics of GC can be depicted more accurately. However, significant differences between both classifications still exist so that they cannot be substituted for each other. So far there is no widely accepted molecular classification of GC. Compared with TCGA classification, ACRG system may have more clinical significance in Chinese GC patients since the samples are mostly from Asian population and show better association with prognosis. The molecular classification of GC may provide the theoretical and experimental basis for early diagnosis, therapeutic efficacy prediction and treatment stratification while their clinical application is still limited. Future work should involve the application of molecular classifications in the clinical settings for improving the medical management of GC.
